These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30505594)

  • 21. Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.
    Rao T S; Raju KVVN; Patnaik SC; Reddy P; Saksena AR; Rajappa S; Mallavarapu KM; Santa A; Gudipudi D; Boleneni N; Usofi Z; Gujjuru S; Smith L; Are C; Nusrath S
    J Surg Oncol; 2021 Jun; 123(7):1547-1557. PubMed ID: 33650697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer.
    Lutfi W; Talamonti MS; Kantor O; Wang CH; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Am J Surg; 2017 Mar; 213(3):521-525. PubMed ID: 28089341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology.
    Olecki EJ; Stahl KA; Torres MB; Peng JS; Dixon M; Shen C; Gusani NJ
    Ann Surg Oncol; 2021 Jun; 28(6):3111-3122. PubMed ID: 33521899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
    Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
    Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma.
    van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP
    Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective review of total neoadjuvant therapy.
    Babar L; Bakalov V; Abel S; Ashraf O; Finley GG; Raj MS; Lundeen K; Monga DK; Kirichenko AV; Wegner RE
    World J Gastrointest Oncol; 2019 Oct; 11(10):857-865. PubMed ID: 31662824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
    Neoptolemos JP; Stocken DD; Dunn JA; Almond J; Beger HG; Pederzoli P; Bassi C; Dervenis C; Fernandez-Cruz L; Lacaine F; Buckels J; Deakin M; Adab FA; Sutton R; Imrie C; Ihse I; Tihanyi T; Olah A; Pedrazzoli S; Spooner D; Kerr DJ; Friess H; Büchler MW;
    Ann Surg; 2001 Dec; 234(6):758-68. PubMed ID: 11729382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
    Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP
    J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Pathologic Response After Total Neoadjuvant Therapy in Patients With Rectal Adenocarcinoma: A National Cancer Database Analysis.
    McDermott DM; Singh SA; Renz PB; Hasan S; Weir J
    Cureus; 2021 Aug; 13(8):e17233. PubMed ID: 34540460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation.
    Anderson JD; Wan W; Kaplan BJ; Myers J; Fields EC
    J Gastrointest Oncol; 2016 Dec; 7(6):1004-1010. PubMed ID: 28078125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Klevebro F; Alexandersson von Döbeln G; Wang N; Johnsen G; Jacobsen AB; Friesland S; Hatlevoll I; Glenjen NI; Lind P; Tsai JA; Lundell L; Nilsson M
    Ann Oncol; 2016 Apr; 27(4):660-7. PubMed ID: 26782957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer.
    He F; Yu L; Ding Y; Li ZH; Wang J; Zheng J; Chen HY; Liu S; Pang XL; Ajani JA; Wan XB
    Cancer Sci; 2020 Nov; 111(11):4205-4217. PubMed ID: 32860448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study.
    Wang T; Chen Y; Zhao L; Zhou H; Wu C; Zhang X; Zhou A; Jin J; Zhao D
    J Cancer; 2021; 12(2):379-386. PubMed ID: 33391434
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
    Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
    Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.